PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors

Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton’s tyrosine kinase and phosphoinositide 3-kinase δ offer opportunities for therapeutic intervention by agent...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:PLoS One
Huvudupphovsmän: Yahiaoui, Anella, Meadows, Sarah A., Sorensen, Rick A., Cui, Zhi-Hua, Keegan, Kathleen S., Brockett, Robert, Chen, Guang, Quéva, Christophe, Li, Li, Tannheimer, Stacey L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Public Library of Science 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5298344/
https://ncbi.nlm.nih.gov/pubmed/28178345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0171221
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk